Why the study?
Does a 3-day continuous intravenous infusion of daunomycin improve complete response rates compared to historical bolus administration in patients with acute nonlymphocytic leukaemia?
Population
19 sequential patients admitted for treatment of acute nonlymphocytic leukaemia (ANLL)
Comparison
3-day continuous intravenous infusion of… vs Institution's past experience with antileukaemic…
Design
Cohort
Authors
Loading...
Supports continuous daunomycin infusion for ANLL induction; leaves open any advantage over bolus in randomized trials.
Does a 3-day continuous intravenous infusion of daunomycin improve complete response rates compared to historical bolus administration in patients with acute nonlymphocytic leukaemia?
Continuous intravenous infusion of daunomycin is an effective remission-induction regimen for acute nonlymphocytic leukaemia, with efficacy comparable to bolus administration.
Lewis et al. (1985) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: